USA flag logo/image

An Official Website of the United States Government

Gold Nanoparticle Contrast Agents: MicroCT of Colon Cancer

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
70484
Program Year/Program:
2006 / SBIR
Agency Tracking Number:
CA108013
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
NANOPROBES, INC.
95 HORSEBLOCK RD YAPHANK, NY 11980-
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 2006
Title: Gold Nanoparticle Contrast Agents: MicroCT of Colon Cancer
Agency: HHS
Contract: 2R44CA108013-02
Award Amount: $887,575.00
 

Abstract:

DESCRIPTION (provided by applicant): This proposal seeks to develop new contrast agents for in vivo microCT x-ray imaging based on non- toxic gold nanoparticles that would provide additional useful features over current agents including: a) longer imaging times, b) higher contrast, and c) targeted, tumor-specific imaging. Physically, gold is a better contrast element than iodine for both microCT and clinical CT because, for microCT the beam's energy spectrum can tailored to be above its 12-14-keV L-edge (e.g. 50 kVp), while for clinical CT it can be tuned to be above gold's 80.7-keV K-edge (e.g., 150 kVp with Cu filtration), thus optimizing the image contrast-to-noise ratio for both applications. Phase 1 work has succeeded in imaging 20 fm blood vessels and obtaining vascular casts in live animals with this approach, never before achieved. Small, orthotopic colon tumors were also detected in vivo using gold nanoparticles. Phamacokinetics and toxicity were also shown to be acceptable. Gold-antibody conjugates were found to be specifically targeted to colon tumor cells in vitro. In Phase II, targeted molecular imaging will be extended to animals. Anti-CEA antibody-gold nanoparticles will be optimized to detect small human colon tumors in a mouse model by microCT. Additionally, vascular molecular markers in tumors will also be targeted. Further toxicity testing will be done and used to demonstrate or refine production of non-toxic gold contrast agents. R&D effort will result in products offered that other investigators can use. The benefits of this work will be: a) the enabling of high resolution in vivo CT contrasted detection and study of colon tumors and their vasculature, b) the introduction of contrast agent products that will then be available to other researchers using microCTs that will enable vascular and targeted imaging, c) to address and overcome the remaining obstacles to make these agents acceptable for human use. If successful, this effort will produce superior blood pool agents and the first targeted CT contrast agent, goals that have been difficult to achieve by other approaches.

Principal Investigator:

James F. Hainfeld
6313442911
hainfeld@bnl.gov

Business Contact:

James Hainfeld
6312059490
hainfeld@nanoprobes.com
Small Business Information at Submission:

NANOPROBES, INC.
NANOPROBES, INC. 95 HORSEBLOCK RD YAPHANK, NY 11980

EIN/Tax ID: 113038451
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No